Related Experiment Video
Updated: Dec 23, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
Severe Thrombocytopenia in a Patient with COVID-19
Eliel Nham1, Jae Hoon Ko1, Byeong Ho Jeong2
1Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Insights
This case study highlights a severe drop in platelet count in a COVID-19 patient treated with multiple drugs. Discontinuing ceftriaxone, levofloxacin, and lopinavir/ritonavir led to platelet recovery, suggesting potential drug-induced thrombocytopenia.
Area of Science:
- Infectious Diseases
- Pharmacology
- Hematology
Background:
- The global spread of Coronavirus disease 2019 (COVID-19) necessitates urgent treatment strategies.
- Empirical antibacterial and antiviral therapies are commonly used due to incomplete understanding of COVID-19's clinical features and potential co-infections.
- Polypharmacy is frequently employed in managing severe COVID-19 cases.
Observation:
- A patient with COVID-19 developed severe thrombocytopenia, characterized by epistaxis and petechiae.
- The patient was concurrently treated with ceftriaxone, levofloxacin, and lopinavir/ritonavir.
- Platelet count dropped critically to 2,000/mm³.
Findings:
- Discontinuation of the three suspect medications (ceftriaxone, levofloxacin, lopinavir/ritonavir) resulted in the recovery of the patient's platelet count.
- This suggests a potential link between the combination of these drugs and the observed severe thrombocytopenia.
Implications:
- While empirical treatment is crucial for emerging infectious diseases like COVID-19, careful consideration of potential adverse drug effects is essential.
- This case underscores the importance of monitoring for drug-induced thrombocytopenia in patients receiving multiple medications.
- Further investigation into the safety profile of combined antibiotic and antiviral therapies in COVID-19 patients is warranted.
Abstract:
Coronavirus disease 2019 (COVID-19) outbreak is spreading rapidly all over the world, being a major threat to public health. Since clinical feature of COVID-19 has not been fully evaluated yet, empirical antibacterial agents are frequently combined for the treatment of COVID-19 in addition to antiviral agents, concerning co-existing bacterial pathogens. We experienced a case of severe thrombocytopenia with epistaxis and petechiae, while treating a COVID-19 patient with ceftriaxone, levofloxacin, and lopinavir/ritonavir. The platelet count decreased to 2,000/mm³ and recovered after discontinuation of the three suspected drugs. In treating a potentially fatal emerging infectious disease, empirical and/or experimental approach would be unavoidable. However, the present case suggests that the possibility of adverse effects caused by polypharmacy should also be carefully considered.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Venous Thrombosis IV: Nursing Management
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Myocarditis III: Medical Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

